PriceTargets.com logo

Silexion Therapeutics - SLXN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $75.00
  • Forecasted Upside: 4,066.67%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.80 As of 02/2/2026 05:00 PM ET
▼ -0.03 (-1.64%)

This chart shows the closing price for SLXN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Silexion Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLXN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLXN

Analyst Price Target is $75.00
▲ +4,066.67% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Silexion Therapeutics in the last 3 months. The average price target is $75.00, with a high forecast of $75.00 and a low forecast of $75.00. The average price target represents a 4,066.67% upside from the last price of $1.80.

This chart shows the closing price for SLXN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Silexion Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/3/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/16/2025Zacks ResearchUpgradeHold
12/15/2025Litchfield Hills ResearchInitiated CoverageBuy
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
3/20/2025Maxim GroupLower TargetBuy ➝ Buy$135.00 ➝ $75.00
11/1/2024Maxim GroupInitiated CoverageBuy$135.00
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Silexion Therapeutics logo
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Read More

Today's Range

Now: $1.80
Low: $1.76
High: $1.85

50 Day Range

MA: $2.37
Low: $1.73
High: $3.17

52 Week Range

Now: $1.80
Low: $1.65
High: $26.70

Volume

15,488 shs

Average Volume

49,018 shs

Market Capitalization

$5.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Silexion Therapeutics?

The following equities research analysts have issued research reports on Silexion Therapeutics in the last year: Litchfield Hills Research, Maxim Group, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for SLXN.

What is the current price target for Silexion Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Silexion Therapeutics in the last year. Their average twelve-month price target is $75.00, suggesting a possible upside of 4,066.7%. Maxim Group has the highest price target set, predicting SLXN will reach $75.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $75.00 for Silexion Therapeutics in the next year.
View the latest price targets for SLXN.

What is the current consensus analyst rating for Silexion Therapeutics?

Silexion Therapeutics currently has 1 sell rating, 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SLXN, but not buy more shares or sell existing shares.
View the latest ratings for SLXN.

What other companies compete with Silexion Therapeutics?

Other companies that are similar to Silexion Therapeutics include FibroBiologics, Genenta Science, VistaGen Therapeutics, Hyperion DeFi and NanoViricides. Learn More about companies similar to Silexion Therapeutics.

How do I contact Silexion Therapeutics' investor relations team?

Silexion Therapeutics' physical mailing address is The Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Medical Center, Jerusalem 9112001, Israel. The company's listed phone number is 972-2-674-3430 and its investor relations email address is [email protected]. The official website for Silexion Therapeutics is silexion.com. Learn More about contacing Silexion Therapeutics investor relations.